PMID- 35664074
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20230916
IS  - 1838-7640 (Electronic)
IS  - 1838-7640 (Linking)
VI  - 12
IP  - 8
DP  - 2022
TI  - Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, 
      and prospects.
PG  - 3719-3746
LID - 10.7150/thno.72594 [doi]
AB  - In recent years, antibody-based cancer therapy has emerged as one of the 
      efficient therapeutic strategies, such as immune checkpoint inhibitors (ICIs), 
      angiogenesis inhibitors, antibody-drug conjugates (ADCs), multi-specific 
      antibodies, and chimeric antigen receptor T (CAR-T) cells, among others. To date, 
      various drug delivery platforms have been developed to improve the 
      bioavailability, delivery convenience, and reduced toxicity towards increased 
      therapeutic efficacy of antibodies. Herein, we emphasize the clinical 
      manifestations of various antibody-based tumor therapies, highlighting their 
      mechanisms and applications for cancer therapy. Further, based on the problems to 
      be solved in the current clinical application of antibodies, and combined with 
      the advanced drug delivery technologies, we discuss the roles of antibody-based 
      drug delivery systems (DDSs) in cancer therapy, such as enhanced patient 
      compliance and regulating the tumor microenvironment for combined therapy. By 
      expounding the importance of DDSs and discussing the challenges and prospects of 
      their implementation, we suggest that pharmaceutical enterprises and scientists 
      develop appropriate antibody-based delivery platforms.
CI  - (c) The author(s).
FAU - Chen, Zhoujiang
AU  - Chen Z
AD  - School of Food and Bioengineering, Institute for advanced study, Chengdu 
      University, Chengdu 610106, Sichuan, PR China.
FAU - Kankala, Ranjith Kumar
AU  - Kankala RK
AD  - Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen 
      361021, Fujian, PR China.
FAU - Yang, Zhiyong
AU  - Yang Z
AD  - Department of Clinical Pharmacy, Affiliated Hospital of Chengdu University, 
      Chengdu University, Chengdu 610081, Sichuan, PR China.
FAU - Li, Wei
AU  - Li W
AD  - School of Basic Medical Sciences, Chengdu University, Chengdu 610106, Sichuan, PR 
      China.
FAU - Xie, Songzhi
AU  - Xie S
AD  - School of Food and Bioengineering, Institute for advanced study, Chengdu 
      University, Chengdu 610106, Sichuan, PR China.
FAU - Li, Hanmei
AU  - Li H
AD  - School of Food and Bioengineering, Institute for advanced study, Chengdu 
      University, Chengdu 610106, Sichuan, PR China.
FAU - Chen, Ai-Zheng
AU  - Chen AZ
AD  - Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen 
      361021, Fujian, PR China.
FAU - Zou, Liang
AU  - Zou L
AD  - School of Food and Bioengineering, Institute for advanced study, Chengdu 
      University, Chengdu 610106, Sichuan, PR China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220501
PL  - Australia
TA  - Theranostics
JT  - Theranostics
JID - 101552395
RN  - 0 (Antibodies)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Antibodies/therapeutic use
MH  - *Drug Delivery Systems
MH  - Humans
MH  - Immune Checkpoint Inhibitors
MH  - Immunotherapy
MH  - *Neoplasms/drug therapy
MH  - Tumor Microenvironment
PMC - PMC9131265
OTO - NOTNLM
OT  - Antibody-based therapy
OT  - Controlled release
OT  - Drug delivery system
OT  - Immunotherapy
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2022/06/07 06:00
MHDA- 2022/06/09 06:00
PMCR- 2022/01/01
CRDT- 2022/06/06 14:09
PHST- 2022/03/04 00:00 [received]
PHST- 2022/04/13 00:00 [accepted]
PHST- 2022/06/06 14:09 [entrez]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - thnov12p3719 [pii]
AID - 10.7150/thno.72594 [doi]
PST - epublish
SO  - Theranostics. 2022 May 1;12(8):3719-3746. doi: 10.7150/thno.72594. eCollection 
      2022.